Table 1. Screening of the Antiproliferative Activity of Aglycone Polyethers on Different Cancer Cell Lines^a.

	IC50 (M)a					IC50 (M)a
cell lines	J1-001-1	J1-001-2	J1-001-3	J1-001-4	cell lines	J1-001-1	J1-001-2	J1-001-3	J1-001-4
T98G (brain cancer)	2.82 × 10–7	6.56 × 10–8	2.86 × 10–7	5.17 × 10–7	A-673 (rhabdomyosarcoma)	1.72 × 10–7	3.18 × 10–8	1.41 × 10–7	2.68 × 10–7
MeWo (skin cancer)	1.70 × 10–6	4.47 × 10–7	1.20 × 10–6	3.30 × 10–6	DU 145 (prostate cancer)	9.38 × 10–7	2.67 × 10–7	1.38 × 10–6	1.93 × 10–6
A-498 (kidney cancer)	7.11 × 10–7	1.73 × 10–7	5.54 × 10–7	7.48 × 10–7	SK-UT-1 (uterine sarcoma)	3.59 × 10–7	3.74 × 10–8	4.31 × 10–7	2.67 × 10–7
SK-MEL-2 (skin cancer)	1.67 × 10–7	5.45 × 10–8	1.45 × 10–7	3.1 × 10–7	MES-SA/Dx-5 (uterine sarcoma)	1.38 × 10–7	1.96 × 10–8	9.15 × 10–8	2.58 × 10–7
SK-HEP-1 (liver cancer)	3.66 × 10–7	1.16 × 10–7	4.55 × 10–7	6.69 × 10–7	A-204 (rhabdomyosarcoma)	6.58 × 10–8	3.94 × 10–9	4.65 × 10–8	2.97 × 10–8
MG-63 (bone cancer)	6.21 × 10–8	8.50 × 10–9	1.12 × 10–7	1.39 × 10–7	G-361 (Melanoman.)	2.74 × 10–7	1.42 × 10–8	3.19 × 10–7	5.48 × 10–7
ACHN (kidney cancer)	1.73 × 10–6	5.17 × 10–7	1.45 × 10–6	2.20 × 10–6	HCT 116 (colon cancer)	2.90 × 10–7	7.58 × 10–8	2.67 × 10–7	5.31 × 10–7
SW 982 (synovial sarcoma)	7.86 × 10–7	4.36 × 10–7	7.46 × 10–7	4.96 × 10–7	SJSA-1 (bone cancer)	2.45 × 10–7	7.64 × 10–8	3.88 × 10–7	2.80 × 10–7
SK-OV-3 (ovary cancer)	1.39 × 10–6	3.9 × 10–7	9.09 × 10–7	1.50 × 10–6	COLO 205 (colon cancer)	2.90 × 10–7	8.21 × 10–8	1.95 × 10–7	1.29 × 10–7
PC-3 (prostate cancer)	6.68 × 10–7	1.24 × 10–7	4.28 × 10–7	7.83 × 10–7	MKN-45 (gastric cancer)	4.85 × 10–7	1.38 × 10–7	3.75 × 10–7	4.58 × 10–7
A549 (lung cancer)	3.21 × 10–7	8.49 × 10–8	2.88 × 10–7	5.57 × 10–7	DOHH2 (lymphoma)	2.61 × 10–9	<4.40 × 10–10	2.09 × 10–9	3.1 × 10–9
OVCAR-4 (ovary cancer)	2.20 × 10–6	1.85 × 10–6	3.16 × 10–6	4.25 × 10–6	K562 (leukemia)	2.81 × 10–8	1.28 × 10–8	3.99 × 10–8	1.06 × 10–7
Calu-3 (lung cancer)	3.48 × 10–7	1.13 × 10–7	3.62 × 10–7	3.59 × 10–7	PAC (pancreas cancer)	6.81 × 10–7	9.33 × 10–8	3.99 × 10–7	3.06 × 10–7
U-87 MG (brain cancer)	2.25 × 10–7	8.63 × 10–9	2.25 × 10–7	8.33 × 10–8	NUGC-4 (gastric cancer)	1.49 × 10–7	1.11 × 10–8	7.71 × 10–8	9.68 × 10–8
Hep 3B2.1-7[Hep3B] (liver cancer)	6.49 × 10–8	8.68 × 10–9	3.32 × 10–8	6.17 × 10–8	Hep G2 (Liver Cancer)	2.42 × 10–7	5.51 × 10–8	2.77 × 10–7	2.21 × 10–7
A375 (melanoman.)	5.36 × 10–7	6.16 × 10–8	2.21 × 10–7	4.90 × 10–7	MIA PaCa-2 (pancreas cancer)	3.10 × 10–8	3.45 × 10–9	2.58 × 10–8	2.45 × 10–8
MD (spleen macrophage)	8.45 × 10–9	1.47 × 10–9	6.83 × 10–9	1.89 × 10–8	Jurkat (lymphoma)	2.88 × 10–7	7.81 × 10–8	1.96 × 10–7	3.88 × 10–7
AHH-1 (lymphoid)	1.44 × 10–6	2.83 × 10–7	1.37 × 10–7	2.37 × 10–6	*MDA-MB-231 (breast cancer)	2.80 × 10–7	2.63 × 10–7	7.10 × 10–7	1.41 × 10–6
MV-4-11 (leukemia)	1.56 × 10–8	7.21 × 10–10	6.8 × 10–9	4.79 × 10–9	*MCF-7 (breast cancer)	3.85 × 10–7	1.65 × 10–8	2.86 × 10–7	3.71 × 10–7

^aIC₅₀ values represent the half-maximal inhibitory concentration compared to control and were determined after exposure of the cells to different drug concentrations for 72 h. Experiments were conducted using the CellTiter-Glo reagent except for those marked by “*”, which were performed using the MTT cytotoxicity assay. All compounds were evaluated in at least three independent experiments. The percentage inhibition was calculated using the following equation: Cell growth inhibition % = [1 – RLU_Compound]/(RLU_0.3%DMSO)] × 100%. Experiments were performed by Genescript Biological Technology Co., Ltd. Bars denote the standard error with n = 3 for each treatment combination. Quality control criteria: doxorubicin on BEL-7402 cells. For more details, see the Supporting Information.